Diana C Lopez1,2, Andrew E Wadley1,3, Nyall R London1,4,5. 1. Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health; Bethesda, Maryland. 2. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio. 3. Howard University College of Medicine, Washington, District of Colombia. 4. Department of Neurosurgery, Johns Hopkins University School of Medicine; Baltimore, Maryland. 5. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine; Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Sinonasal malignancies are rare and understudied, often diagnosed at late stages, and may behave aggressively. This review explores investigative diagnostic, therapeutic, and scientific advances specific to sinonasal undifferentiated carcinoma (SNUC), intestinal-type adenocarcinoma (ITAC), and olfactory neuroblastoma (ONB). RECENT FINDINGS: A number of studies have recently contributed more robust knowledge of the genetic and molecular landscapes of SNUC, ITAC, and ONB. These analyses have identified SMARCB1 and IDH2 mutations in SNUC, potentially allowing for the tumor's subdivision. Recent studies have also defined a role for induction chemotherapy in SNUC. Somatic mutations for ITAC have been identified and may be potentially targetable with FDA approved therapies. Studies defining the tumor microenvironment for ITAC and ONB have introduced the possibility of immune checkpoint inhibition for these tumor types. SUMMARY: Studies reviewed here detail promising results of the most current and novel characterization of SNUC, ITAC, and ONB genetic and molecular landscapes, which have informed ongoing therapeutic discovery. With continued multi-institutional efforts, the field of sinonasal tumor research will achieve higher disease control and improved treatment outcomes for patients afflicted with these rare cancers.
PURPOSE OF REVIEW: Sinonasal malignancies are rare and understudied, often diagnosed at late stages, and may behave aggressively. This review explores investigative diagnostic, therapeutic, and scientific advances specific to sinonasal undifferentiated carcinoma (SNUC), intestinal-type adenocarcinoma (ITAC), and olfactory neuroblastoma (ONB). RECENT FINDINGS: A number of studies have recently contributed more robust knowledge of the genetic and molecular landscapes of SNUC, ITAC, and ONB. These analyses have identified SMARCB1 and IDH2 mutations in SNUC, potentially allowing for the tumor's subdivision. Recent studies have also defined a role for induction chemotherapy in SNUC. Somatic mutations for ITAC have been identified and may be potentially targetable with FDA approved therapies. Studies defining the tumor microenvironment for ITAC and ONB have introduced the possibility of immune checkpoint inhibition for these tumor types. SUMMARY: Studies reviewed here detail promising results of the most current and novel characterization of SNUC, ITAC, and ONB genetic and molecular landscapes, which have informed ongoing therapeutic discovery. With continued multi-institutional efforts, the field of sinonasal tumor research will achieve higher disease control and improved treatment outcomes for patients afflicted with these rare cancers.
Authors: J Perez-Escuredo; A Lopez-Hernandez; M Costales; F Lopez; S P Ares; B Vivanco; J L Llorente; M A Hermsen Journal: Rhinology Date: 2016-09 Impact factor: 3.681
Authors: Tawfiq Khoury; David Jang; Ricardo Carrau; Neal Ready; Ian Barak; Ralph Abi Hachem Journal: Int Forum Allergy Rhinol Date: 2018-11-09 Impact factor: 3.858
Authors: Jhudit Pérez-Escuredo; Jorge García Martínez; Cristina García-Inclán; Blanca Vivanco; María Costales; César Álvarez Marcos; José Luis Llorente; Mario A Hermsen Journal: Cell Oncol (Dordr) Date: 2011-01-18 Impact factor: 6.730
Authors: Vincent Cracolici; Eric W Wang; Paul A Gardner; Carl Snyderman; Stacey M Gargano; Simion Chiosea; Aatur D Singhi; Raja R Seethala Journal: Head Neck Pathol Date: 2021-04-30
Authors: Rocío García-Marín; Sara Reda; Cristina Riobello; Virginia N Cabal; Laura Suárez-Fernández; Blanca Vivanco; Fernando López; José L Llorente; Mario A Hermsen Journal: Vaccines (Basel) Date: 2020-04-28